Heart Health Tips: Is high intensity workout advisable for stroke survivors? Here's what you need to know

Your competent? doctor WILL 100% GUARANTEE that HIT will not cause a stroke? By verifying that your aneurysms will not blow out?

Do you really want to do high intensity training?

Because Andrew Marr blames high-intensity training for his stroke. 

Can too much exercise cause a stroke?

The latest here:

Heart Health Tips: Is high intensity workout advisable for stroke survivors? Here's what you need to know

While the importance of exercise in stroke rehabilitation cannot be overstated, experts on Saturday affirmed that short bursts of high-intensity interval training (HIIT) could be more effective than continuous moderate physical exercise. When a stroke occurs, blood flow to the brain is disrupted, leading to damage that can impact physical and cognitive functions. Exercise plays a crucial role in the rehabilitation process by promoting neuroplasticity, where the brain reorganises itself to recover lost functions.

HIIT involves repeated one-minute bursts of intense exercise followed by short recovery periods. Use of a stationary bike, treadmill, bodyweight, kettlebell, dumbbells, or jumping rope are some examples of HIIT workouts. "HIIT represents a paradigm shift in rehabilitation, particularly for stroke recovery," Dr Vikram Huded, HOD and Director and Clinical Lead, Interventional Neurology, Narayana Health City, told IANS.

"Unlike traditional continuous moderate exercise, HIIT enhances cardiovascular health more efficiently by pushing the body to adapt to short, intense bursts of activity," added Dr Raghvendra Ramdasi, Consultant Neurosurgeon, Jaslok Hospital, Mumbai. Several studies have shown that exercising after a stroke offers several health benefits, including reduced risk of stroke recurrence and boosted overall recovery.

A recent research, published in the journal Stroke, showed that one-minute bursts of high-intensity interval training over 19 minutes were more effective than traditional moderate exercise for improving the body's aerobic fitness after a stroke. Evidence suggests that HIIT can accelerate cardiovascular recovery and improve overall physical endurance more effectively than conventional methods. 

Ramdasi told IANS the method not only boosts heart and lung capacity but also improves circulation, which is vital for brain recovery. However, HIIT may not be suitable for everyone, said the experts. "Patients with severe cardiovascular conditions or those who are not yet physically stable post-stroke should avoid this form of exercise until they have regained a certain level of baseline fitness," Huded said. Ramdasi said patients who have regained some mobility and are medically stable benefit most from HIIT.

The experts also urged stroke patients to perform "any exercise regimen, particularly HIIT, according to an individual's abilities and under supervision of an expert to avoid potential risks" They also advised to begin with lower intensity and gradually increase as tolerance improves.  

Mitochondrial and peroxisomal fission in cortical neurogenesis

 Ask your competent? doctor if this is enough to UNDERSTAND EXACTLY HOW TO MAKE NEUROGENESIS REPEATABLE ON DEMAND! And then CREATE PROTOCOLS TO DO THAT!

Your competent? stroke medical 'professionals' have been working on mitochondrial fission for over a decade, right? Oh NO!  You just realized the whole stroke medical world is FUCKING INCOMPETENT! Your solution is to not have a stroke! 

• mitochondrial fission (1 post to November 2013)

Mitochondrial and peroxisomal fission in cortical neurogenesis

Author links open overlay panel, ,

https://doi.org/10.1016/j.biocel.2025.106774

Get rights and content

Abstract

The human brain is unique in its cellular diversity, intricate cytoarchitecture, function,and complex metabolic and bioenergetic demands, for which mitochondria and.peroxisomes are essential. Beyond providing energy in the form of ATP, mitochondria.and peroxisomes are multifunctional organelles that coordinate various signaling.pathways central to neurogenesis. The dynamic morphological changes of the.mitochondrial network have been linked to the regulation of bioenergetic and metabolic.states. Specific protein machineries are dedicated to mitochondrial fission and fusion,which allow for organelle distribution during cell division, organelle repair, and.adaptation to environmental stimuli (excellent reviews have been published on these.topics [Kondadi & Reichert 2024; Giacomello et al. 2020; Tilokani et al. 2018; Kraus et.al. 2021; Navaratnarajah et al. 2021]). This review focuses primarily on the machinery.involved in mitochondrial and peroxisomal fission. Mitochondrial fission enables cells to.detect and respond to external signals, making it a critical determinant of cell fate.decisions (Iwata et al. 2023; Iwata et al. 2020; Khacho et al. 2016; King et al. 2021;Prigione & Adjaye 2010; Vantaggiato et al. 2019; Rosenberg et al. 2023, Kleele et al.2021, Kraus et al., 2021). The connection between alterations in peroxisomal fission.and metabolic changes associated with cellular differentiation remains less clear. Here,we provide an overview of the functional and regulatory aspects of the mitochondrial.and peroxisomal fission machineries and provide insight into the current mechanistic.understanding by which mitochondrial and peroxisomal fission influence neurogenesis.

Introduction

The human brain is unique in its cellular diversity, intricate cytoarchitecture, function, and complex metabolic and bioenergetic demands, for which mitochondria and peroxisomes are essential. Mitochondria are multifunctional organelles that coordinate various signaling pathways central to neurogenesis. The dynamic morphological changes of the mitochondrial network have been linked to the regulation of bioenergetic and metabolic states. Specific protein machinery is dedicated to mitochondrial fission and fusion, allowing organelle distribution during cell division, organelle repair, and adaptation to environmental stimuli (excellent reviews have been published on these topics [Kondadi & Reichert 2024; Giacomello et al. 2020; Tilokani et al. 2018; Kraus et al. 2021; Navaratnarajah et al. 2021]). In parallel, peroxisomes contain over 50 different enzymes which regulate metabolic functions that are critical for neurogenesis (Berger et al., 2016, Hulshagen et al., 2008). Peroxisomes share many of the components of their fission machinery with the mitochondria and undergo fission to help meet metabolic demands in response to environmental stimuli (Schrader et al. 2016). This review focuses primarily on the machinery involved in mitochondrial and peroxisomal fission. Mitochondrial fission has been identified as a critical determinant of cell fate decisions (Iwata et al., 2023, Iwata et al., 2020, Khacho et al., 2016, King et al., 2021, Prigione and Adjaye, 2010, Vantaggiato et al., 2019, Kraus et al., 2021). The connection between alterations in peroxisomal fission and metabolic changes associated with cellular differentiation remains less clear. Here, we provide an overview of the functional and regulatory aspects of the mitochondrial and peroxisomal fission machinery and provide insight into the current mechanistic understanding by which mitochondrial and peroxisomal fission influence neurogenesis.

Access through your organization

What Is The 2 Finger Test In Dementia?

 Most stroke survivors would fail this if they have a disability in one hand, so make sure you decline to take it. By declining it, you prove you don't have dementia.

I refused to allow my Mom at 95 to take a cognitive test, she only has an 8th grade education and thus would get labeled incorrectly.

Similar to Catch-22; The term "catch-22" comes from the 1961 novel by Joseph Heller, where it describes a situation in the military where a pilot could avoid flying combat missions by claiming insanity, but the very act of claiming insanity would prove his sanity and thus he would have to continue flying.

Other sources claim this is it since the video completely failed at telling us about it! 

The "2-finger test" for dementia, often called the Interlocking Finger Test, assesses coordination, memory, and motor skills by having someone replicate a specific finger gesture, like interlocking fingers or touching thumb to index finger repeatedly, to spot early signs of cognitive decline, though it's a screening tool, not a definitive diagnosis, revealing issues with processing, memory, or motor control often seen in dementia. Difficulty performing these simple tasks (slowness, hesitation, errors) can signal underlying neurological changes.

What Is The 2 Finger Test In Dementia?

Effects of vestibular rehabilitation and dual-task training on balance and gait in sub-acute and chronic stroke survivors

 

 Ask your competent? doctor EXACTLY HOW THIS WILL GET YOU RECOVERED! Doesn't know about it? You don't have a functioning stroke doctor!

Effects of vestibular rehabilitation and dual-task training on balance and gait in sub-acute and chronic stroke survivors

B. Nairn ∙ D. Bamiou ∙ D. Kaski ∙ N. Koohi ∙ M. Pavlou

Cite

• • Set Alert
  • Get Rights
  • Reprints

  Previous articleNext article

Purpose: Previous studies have indicated that vestibular rehabilitation therapy (VRT) including balance physiotherapy, improves dynamic balance of stroke survivors through its effect on the vestibular system. Despite this evidence, VRT is rarely included in stroke rehabilitation guidelines due to limited evidence and high-quality studies. We aim to answer the question, what are the effects of VRT and/or dual-task (DT) training, on balance and gait for reducing the risk of falls, among sub-acute and chronic stroke survivors?

Get full text access

Behaviour change approaches within digital health technology-based interventions to facilitate early upper limb rehabilitation post stroke: a scoping review

 Ask your competent? doctor EXACTLY HOW THIS WILL GET YOU RECOVERED! Doesn't know about it? You don't have a functioning stroke doctor!

Behaviour change approaches within digital health technology-based interventions to facilitate early upper limb rehabilitation post stroke: a scoping review

H.J. Gooch ∙ R.C. Stockley

Cite

• • Set Alert
  • Get Rights
  • Reprints

  Previous articleNext article

Purpose: Digital health technologies (DHTs) have the potential to support individuals to make changes to their behaviour in the early months following a stroke that will enable engagement with the intensive upper limb rehabilitation that is crucial to their recovery. In the absence of review literature in this area this scoping review aimed to identify and explore the use of behaviour change approaches in DHT-based interventions for upper limb rehabilitation in the first six months after stroke.

Get full text access

Daily omega-3 slows biological aging by almost 4 months

 

 Didn't your competent? doctor prescribe this stuff for you a long time ago?

• omega-3 (98 posts to June 2012)

Daily omega-3 slows biological aging by almost 4 months

               ByAndrew (Drew) Rhoades

Fact checked byCarol L. DiBerardino, MLA, ELS

Key takeaways:

• A single gram of omega-3 daily over 3 years slowed biological aging by 2.9 to 3.8 months.
• The effects on biological aging were even greater when omega-3 was combined with daily vitamin D and exercise.

Consuming just 1 g of omega-3 a day may moderately slow down biological aging, an analysis published in Nature Aging showed.

The researchers further found that combining this strategy with exercise and vitamin D could be even more effective at slowing such aging.

Data derived from: Bischoff-Ferrari H, et al. Nat Aging. 2025;doi:10.1038/s43587-024-00793-y.

Certain dietary habits, such as greater consumption of ultraprocessed foods, have been shown to influence biological aging.

Heike A. Bischoff-Ferrari, MD, MPH, DrPH, chair of geriatrics and aging research at the University of Zurich in Switzerland, and Steve Horvath, PhD, a principal investigator at the Altos Labs Cambridge Institute of Science, told Healio in a joint email that the observed effects may seem small but, “if sustained, may have relevant effects on population health.”

The researchers wrote that prior observational and smaller studies have tied omega-3, vitamin D and exercise “to modulation of epigenetic clock measures of aging and omega-3 to [DNA methylation (DNAm)] changes.”

In the current post-hoc analysis, Bischoff-Ferrari and colleagues assessed the effects of omega-3, vitamin D and exercise on four DNAm clocks — PhenoAge, GrimAge, GrimAge2 and DunedinPACE — over 3 years during a clinical trial composed of 777 participants aged 70 years or older from Switzerland.

In the DO-HEALTH trial, which included eight different test groups, participants received:

• 1 g of omega-3 daily;
• 2,000 international units of vitamin D daily; and/or
• a 30-minute home exercise program three times a week.

The interventions were either combined or done alone.

Bischoff-Ferrari and colleagues found that omega-3 alone slowed the PhenoAge, GrimAge2 and DunedinPACE clocks.

The standardized effects of omega-3 on these clocks ranged from a reduction of 0.16 (95% CI, 0.02 to 0.3) to 0.32 (95% CI, 0.06 to 0.59) units, or 2.9 to 3.8 months, from baseline to year 3.

The finding was not dependent on factors like participants’ age, BMI or sex, according to the researchers.

Vitamin D supplementation alone and exercise alone did not reduce any of the four biological clocks.

However, the two interventions combined with omega-3 either individually or altogether slowed PhenoAge, with intervention effects ranging from a reduction of 0.24 to 0.32 units.

The researchers noted that the data build upon past findings from the trial, which indicated that omega-3 alone reduced infections and the rate of falls by 10% each and the three interventions combined reduced prefrailty and invasive cancer by 39% and 61%, respectively.

They added that participants who started with lower omega-3 levels experienced larger epigenetic shifts, which “further strengthens the case for personalized approaches.”

“This suggests that baseline nutritional status may modulate the extent of epigenetic responsiveness, emphasizing the potential of omega-3 as a targeted intervention to influence DNAm age and, by extension, biological aging,” they wrote.

Bischoff-Ferrari and colleagues highlighted a couple limitations of the analysis. For example, the study sample did not reflect the general populations of adults aged older than 70 years, and there is no gold-standard measurement for biological aging.

Still, the findings support “these three public health strategies as a combined solution at the public health level to extend health span in older adults,” Bischoff-Ferrari and Horvath told Healio. “Further, these strategies are affordable and safe, as shown in DO-HEALTH over a 3-year follow-up.”

Reference:

• Omega-3s can slow down aging process. https://www.news.uzh.ch/en/articles/media/2025/omega-3s-aging-process.html. Published Feb. 4, 2025. Accessed Feb. 13, 2025.

Sources/Disclosures

Collapse

Source:

Bischoff-Ferrari H, et al. Nat Aging. 2025;doi:10.1038/s43587-024-00793-y.

Disclosures: Bischoff-Ferrari reports no relevant financial disclosures. Please see the study for all other authors’ relevant financial disclosures.       

Intensive BP lowering did not improve functional outcomes after EVT for stroke

 Because our incompetent stroke medical 'professionals' still haven't figured out an EXACT BLOOD PRESSURE MANAGEMENT PROTOCOL post stroke! And YOU bear the failure of that! Hope your competent? doctor guesses correctly because the poor outcome happens to you! Your doctor gets off scot-free and still gets paid! My non-medical thinking on this is that by doing this you are vastly lowering the oxygen supply to the brain thus hastening the neuronal cascade of death!

• blood pressure management (90 posts to June 2017)

Intensive BP lowering did not improve functional outcomes after EVT for stroke

               ByScott Buzby

Fact checked byRichard Smith

Key takeaways:

• Intensive BP lowering after endovascular thrombectomy for stroke did not improve functional outcomes.
• The trial was halted early due to possible harm from the intervention.

Intensive BP lowering after successful endovascular thrombectomy for acute anterior circulation ischemic stroke did not improve 90-day functional outcomes vs. standard BP control, a speaker reported.

The results of the IDENTIFY trial, which was halted early due to safety concerns, were presented at the International Stroke Conference.

Intensive BP lowering after endovascular thrombectomy for stroke did not improve functional outcomes. Image: Adobe Stock

“Endovascular thrombectomy (EVT) has become the standard treatment for acute ischemic stroke due to large vessel occlusion. However, although recanalization can be achieved in more than 80% of patients who had received EVT, more than half of these patients remained functional dependence after treatment,” Bo Wu, MD, professor of neurology at West China Hospital of Sichuan University, in Chengdu, China, said during a presentation. “According to some previous evidence, we hypothesize that the effect of blood pressure on functional outcomes might be affected by time. For example, subgroup analyses of the ENCHANTED2/MT indicated significant adverse effect of intensive BP management in patients who achieved recanalization beyond 6 hours after onset, but not in those within 6 hours.”

For the present trial, Wu and colleagues investigated the impact of intensive BP lowering among 600 Chinese patients with acute ischemic stroke who underwent successful EVT within 6 hours of symptom onset. Participants were randomly assigned to intensive BP lowering with a target lower than 130 mm Hg or standard care with a target lower than 180 mm Hg for 24 hours after EVT.

The primary outcome was unfavorable functional outcomes at 90 days, defined as a modified Rankin score of 3 to 6.

Xuening Zhang, PhD, research assistant in the department of neurology at West China Hospital of Sichuan University, reported that the trial was terminated early, per recommendations from an independent data monitoring committee, after completing the first 90 days of follow-up for the first 383 patients. Termination was due to neutral results and possible harmful effects.

The mean age of the cohort was 72 years and nearly half were women.

Approximately 60% of participants had cardioembolic stroke and thrombolysis was performed in approximately 42% of patients. More than half underwent EVT under general anesthesia, according to the presentation.

Although significantly lower BP was achieved in the intensive BP lowering group, risk for the primary outcome was not significantly different compared with the standard BP lowering group (RR = 1.05; 95% CI, 0.92-1.2; P = .45).

In adjusted analyses, the researchers observed increased risk for both severe disability, defined as modified Rankin score of 4 to 5 (RR = 1.45; 95% CI, 1.1-1.9; P = .009), and death and severe disability (RR = 1.25; 95% CI, 1.07-1.45; P = .005) among participants assigned to intensive BP lowering compared with standard BP lowering.

“Existing randomized trials have explored several potential systolic BP targets after EVT. No sufficient evidence supports intensive BP management after successful EVT, regardless of the duration of the ischemic period,” Zhang said during the presentation. “Additionally, there is a high rate of cardioembolism in our trial, suggesting that blood pressure reduction to below 130 mm Hg did not benefit these patients.”

Published by:

Sources/Disclosures

Collapse

Source:

Zhang X, et al. LB17. Presented at: International Stroke Conference; Feb. 5-7, 2025; Los Angeles (hybrid meeting).

Disclosures: Wu and Zhang report no relevant financial disclosures.       

Coffee Has A Surprising Effect On Mental Health from PsyBlog

 

And I'm doing it to lower my risk of dementia and Parkinsions. This research is good news for me.

How coffee protects against Parkinson’s Aug. 2014  

Coffee May Lower Your Risk of Dementia Feb. 2013

Coffee drinkers rejoice! Drinking coffee could lower the risk of Alzheimer’s disease 

And this: Coffee's Phenylindanes Fight Alzheimer's Plaque December 2018

I think I'm in this category:  I never get the jitters or flushed skin.

Genetics determine how much coffee you can drink before it goes wrong

I'm doing a 12 cup pot of coffee a day to lessen my chances of dementia and Parkinsons. Tell me EXACTLY how much coffee to drink for that and I'll change. Yep, that is a lot more than the 400mg. suggested limit, I don't care! Preventing dementia and Parkinsons is vastly more important than whatever problems it can cause! 

The latest here:

Coffee Has A Surprising Effect On Mental Health

How coffee consumption is linked to both mental and physical health.

Moderate coffee consumption is linked to reduced depression risk and lower levels of Parkinson’s and dementia.

Not only that, but the review of more than 200 studies found that drinking 3 to 4 cups of coffee a day is linked to many other benefits.

These include lower levels of heart disease, reduced risk of some cancers, diabetes and liver disease.

The study’s authors write:

“Coffee consumption was consistently associated with a lower risk of Parkinson’s disease, even after adjustment for smoking, and across all categories of exposure.

Decaffeinated coffee was associated with a lower risk of Parkinson’s disease, which did not reach significance.

Consumption had a consistent association with lower risk of depression and cognitive disorders, especially for Alzheimer’s disease.”

Coffee was also associated with a lower risk of several cancers:

• prostate cancer,
• endometrial cancer,
• skin cancer,
• and liver cancer,

Risk of type 2 diabetes, gallstones and gout was lower in those drinking coffee as well.

Coffee’s apparent effect was particularly strong for liver conditions, such as cirrhosis.

The evidence for drinking decaffeinated coffee was not as strong.

So, if you don’t drink coffee already, should you start?

Writing in a linked commentary, Professor Eliseo Guallar, an expert in public health, gives the answer:

“Should doctors recommend drinking coffee to prevent disease?

Should people start drinking coffee for health reasons?

The answer to both questions is “no.” “

But if you do already drink coffee, then how much should you drink?

Professor Guallar explained:

“…the lowest risk of disease is associated with drinking three to five cups of coffee a day.

Higher intake may reduce or reverse the potential benefit, and there is substantial uncertainty, both in individual studies and in meta-analyses, about the effects of higher levels of intake.

Conclusions on the safety of coffee should thus be restricted to moderate intake, generally considered as ≤400 mg of caffeine a day (about four or five coffee drinks).”

The research was an ‘umbrella review’ which is a kind of review of the reviews.

It aggregates data from lots of different studies including many participants.

However, the way the studies were designed, it cannot tell us that drinking coffee causes these health benefits.

It just tells us there is a link to be explained.

The study was published in The British Medical Journal (Poole et al., 2017).

GLP-1 may have potential to improve poststroke outcomes, prognosis

 You're living in la-la land if you think your doctors and hospital implement research without YOU insisting it get tried. 

GLP-1 may have potential to improve poststroke outcomes, prognosis

               ByScott Buzby

Fact checked byRichard Smith

Key takeaways:

• Liraglutide may improve outcomes and prognosis after minor stroke/transient ischemic attack in patients with diabetes.
• However, the trial was halted prematurely and the data should be interpreted with caution.

The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor stroke or transient ischemic attack, a speaker reported.

However, the LAMP study, presented at the International Stroke Conference, was terminated early due to slow enrollment and cost.

Data were derived from Zhu H, et al. LB44. Presented at: International Stroke Conference; Feb. 5-7, 2025; Los Angeles (hybrid meeting).

“Diabetes increases the [incidence] and recurrence of stroke by two to four times. But insulin or sulfonylurea-based treatment for glycemic control did not reduce the risk of microvascular complications such as myocardial infarction and ischemic stroke. Even with 3 weeks of dual antiplatelet therapy, 12.8% of diabetic patients with minor acute ischemic stroke experienced recurrence within 90 days,” Hui-Li Zhu, MD, associate professor at The First Affiliated Hospital of Jinan University, Guangzhou, China, said during a presentation. “Liraglutide is a synthetic long-acting GLP-1 receptor agonist, and has the ability to cross the blood-brain barrier. Our previous study showed liraglutide decreased the infarct volume and improved neurologic deficits in a rat model of [middle cerebral artery] occlusion. ... Both basic research and clinical studies have suggested that GLP-1 receptor agonists may have the potential to improve stroke recurrence and prognosis.”

LAMP was a multicenter, randomized controlled, prospective trial designed to evaluate the efficacy and safety of liraglutide (Victoza/Saxenda, Novo Nordisk) for the prevention of recurrent stroke after minor ischemic stroke or high-risk TIA in patients with diabetes.

The LAMP study was terminated early due to a lower-than-expected enrollment and financial constraints, which prevented completion within the planned timeframe or target sample size, according to the presentation.

Overall, 636 patients hospitalized with minor ischemic stroke or high-risk TIA within 24 hours of symptom onset were included in the study and were randomly assigned to liraglutide or usual care.

Individuals assigned to liraglutide were provided ascending daily doses of the drug, starting with 0.6 mg and rising to 1.8 mg by day 30.

The primary endpoint was occurrence of new strokes within 90 days of index stroke.

Baseline characteristics were balanced between the liraglutide and usual care groups (mean age, 64 years; 36% women; 91% with history of diabetes; mean baseline HbA1c, 8.2%). The average BMI was approximately 24 kg/m² and one-third of patients were currently smoking.

Subsequent new stroke occurred in 13.8% of the usual care arm compared with 7.9% of the liraglutide arm, which in the intention-to-treat analysis translated to a hazard ratio of 0.56 favoring liraglutide (95% CI, 0.34-0.91; P = .02). However, due to insufficient sample size, statistical power was only 67%.

In secondary analysis, the researchers reported that after minor ischemic stroke or high-risk TIA, individuals with diabetes assigned to liraglutide were more likely to achieve a modified Rankin score of 1 or less at 90 days compared with usual care (OR = 1.95; 95% CI, 1.28-3; P = .002). Similarly, liraglutide was associated with greater likelihood to achieve a modified Rankin score of 2 or less compared with usual care (OR = 1.77; 95% CI, 1.06-3.02; P = .032).

“Among Chinese patients with minor acute ischemic stroke or high-risk TIA who were diagnosed with type 2 diabetes, treatment with liraglutide probably reduced the risk of stroke recurrence and improved outcomes at 90 days,” Zhu said during the presentation. “Careful interpretation of these early terminated study results is warranted, and additional research is required to confirm these potential benefits. The LAMP study is the first and largest-scale trial investigating GLP-1 receptor agonists in patients with ischemic stroke, offering some valuable insights into their potential benefits for improving patient outcomes.”

Published by:

Sources/Disclosures

Collapse

Source:

Zhu H, et al. LB44. Presented at: International Stroke Conference; Feb. 5-7, 2025; Los Angeles (hybrid meeting).

Disclosures: Zhu reports no relevant financial disclosures.       

Neural stem cell transplant improves outcomes for chronic ischemic stroke at 12 months

 Your competent? doctor figured out how to use this earlier research to get you recovered, right? NO? So, YOU DON'T HAVE A FUNCTIONING STROKE DOCTOR, DO YOU?

Neural stem cells sustain natural killer cells that dictate recovery from brain inflammation January 2016 Almost a decade and your doctor is still clueless on how to get you recovered?

The latest here:

Neural stem cell transplant improves outcomes for chronic ischemic stroke at 12 months

               ByRobert Herpen, MA

Fact checked byShenaz Bagha

Key takeaways:

• At 12 months, patients demonstrated improved neurological function and better gait speed.
• All adverse events, which initially worsened from baseline, spontaneously resolved.

Transplantation of neural stem cells improved neurologic and motor function for adults with chronic ischemic stroke at 12 months, according to a study presented at the International Stroke Conference.

“There are approximately 7 million chronic stroke survivors in the United States living with severe disability and little hope for recovery,” Gary K. Steinberg, MD, PhD, founder and co-director of the Stanford Stroke Center, told Healio.

New research has determined that neural stem cell implants improve outcomes at 12 months for those suffering chronic stroke. Image: Adobe Stock

As no other treatment aside from vagus nerve stimulation exists to restore function in patients with chronic stroke, Steinberg and colleagues sought to investigate the safety and efficacy of intracerebral transplantation of NR1, human embryonic-derived neural stem cells.

Their first-in-human clinical trial, which spanned 12 months, included 18 adults who were 6 to 60 months post-ischemic subcortical middle cerebral arterial stroke and recorded a Modified Rankin Scale score of 3 or 4. All participants were transplanted with 2.5 million, 5 million, 10 million or 20 million of NR1, with the primary outcome being total adverse events at 12 months as well as change in total Fugl-Meyer motor score (FMMS, 0-100) in both upper and lower extremities compared with baseline at 12 months. Secondary outcomes included performance on a gait speed test, Barthel Index (BI), NIH Stroke Scale score (NIHSS), Fluid-attenuated inversion recovery (FLAIR) MRI, resting state fMRI and Fludeoxyglucose F 18 positron emission tomography (18F FDG PET).

Participants recorded mean increases of 12.1 points for total FMMS, 7.4 points for upper extremity FMMS, 4.7 points for lower extremity FMMS, along with mean changes of 7.7 points for BI, mean NIHSS improvement of 1.77, as well as substantial improvement in gait speed at 12 months.

Data further showed that 14 of 18 participants had a new transient FLAIR signal in premotor cortex that resolved at the 2-month mark, indicative of sustained neurologic recovery, the researchers wrote.

Steinberg and colleagues also reported improved functional sensorimotor connectivity via resting state fMRI as well as increased activity in the ipsilesional motor cortex and contralesional cerebellum confirmed via 18F FDG PET.

Adverse events such as headache, expressive aphasia and asymptomatic chronic subdural hygroma, which worsened from baseline, eventually spontaneously resolved, according to the researchers.

“Our study demonstrated that intracerebral transplantation of NR1 neural stem cells in 18 patients markedly improved neurologic function at 12 months,” Steinberg told Healio. “If confirmed in larger randomized studies, this therapy has the potential to revolutionize chronic stroke care.”

Sources/Disclosures

Collapse

Source:

Steinberg GK, et al. First-in-human phase 1/2a study of intracerebral transplantation using embryonic-derived neural stem cells (NR1) for chronic ischemic stroke:12 months outcomes. Presented at: International Stroke Conference; Feb. 5-7, 2025; Los Angeles.

Disclosures: Steinberg reports acting as a consultant for Recursion, Surgical Theater, Zeiss and previously for SanBio; and receiving royalties for or as patent beneficiary of Peter Lazic. Please see the study for all other authors’ relevant financial disclosures.        

A Massachusetts man became the first person to try intranasal foralumab under an expanded access program for people with moderate Alzheimer's disease, Tiziana Life Sciences said.

 With your extra risk of dementia post stroke, you doctor has a lot of work to do to prevent dementia! YOUR DOCTOR'S RESPONSIBILITY! Should you be taking this as a preventative? WHY THE FUCK WON'T YOUR DOCTOR FIND THAT OUT? Don't let your doctor weasel out of that! Your doctors have had over a decade to accomplish that! Were they competent at that or not?

1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.

2. Then this study came out and seems to have a range from 17-66%. December 2013.`    

3. A 20% chance in this research.   July 2013.

4. Dementia Risk Doubled in Patients Following Stroke September 2018

5. Brain Bleeds Double Dementia Risk February 2025

The latest here:

A Massachusetts man became the first person to try intranasal foralumab under an expanded access program for people with moderate Alzheimer's disease, Tiziana Life Sciences said.

One paragraph from there:

Dr. Howard Weiner, Co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital, a founding member of Mass General Brigham healthcare system commented “Foralumab, administered via a novel intranasal delivery method, aims to target immune system dysregulation associated with Alzheimer’s disease, potentially slowing disease progression and improving cognitive function. The recent coverage in the News underscores the growing recognition of Foralumab’s promise in the field of neurodegenerative diseases.”

The Influence of Therapy Enriched with the ErigoPro Table and Motor Imagery on the Body Balance of Patients After Stroke—A Randomized Observational Study

 What is your competent? doctor's EXACT PROTOCOL TO RECOVER BALANCE? Is there any at all? Or are you just being thrown to the wolves?

The Influence of Therapy Enriched with the ErigoPro Table and Motor Imagery on the Body Balance of Patients After Stroke—A Randomized Observational Study

Brain Sciences

• March 2025
• 15(3):275

DOI:10.3390/brainsci15030275

• License
• CC BY 4.0

Authors:

Anna Olczak

• Wojskowy Instytut Medyczny

Raquel Carvalho

• Cooperativa de Ensino Superior Politécnico e Universitário

Adam Stępień

Józef Mróz

Abstract and Figures

Purpose: 

Impaired balance leads to loss of function, e.g., the inability to walk safely. Therefore, restoring balance is a common goal of rehabilitation after a stroke. An innovative motor imaging and robotic device, the Erigo®Pro walking table, was used to improve balance in patients who had suffered an acute stroke. 

Materials and Methods: 

Sixty-six stroke patients in the acute phase with an average age of 64.85 ± 18.62 years were randomly assigned to one of three groups (22 subjects each) and treated with different therapies (conventional, conventional with Erigo®Pro, and conventional with Erigo®Pro enriched with motor imaging). The duration of therapy was two weeks. Patients were assessed before and after completion of therapy. The study used the trunk stability test and the Berg Balance Scale to assess balance, and the Riablo™ device to measure static balance. In addition, an assessment of the superficial tension of the transversus abdominis and multifidus muscles was performed. The clinical trial registration URL unique identifier was NCT06276075. Results: In each of the groups studied, the therapies applied resulted in significant improvement in functional assessment of trunk stability and balance (TCT < 0.001 and BBS < 0.001). The assessment of balance in the frontal (p = 0.023) and sagittal (p = 0.074) planes with the Riablo™ device confirmed the superiority of motor imaging-enhanced therapy at the level of a statistical trend. The tension of the transversus abdominis was higher at the second measurement (M = 14.41; SE = 3.31). 

Conclusions: Motor imagery-enhanced therapy is most important, both for trunk stability and functional improvement of body balance parameters and for increasing transversus abdominis muscle tension.

The flow of participants through each stage of the study.

… 

Erigo®Pro device in use during therapy.

… 

Riablo™ device with Luna EMG in use during examination of a patient.

… 

Biometric data of study population and clinical control group.

… 

+1

Summary of results of analysis of variance.

… 

Figures - available via license: Creative Commons Attribution 4.0 International